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INTRODUCTION
"Plastic Surgery is an ocean. One life time is not
 enough to unravel its deepest secrets."
Perhaps no other problem in Plastic Surgery is so aptly described by 
this statement as that of the keloid.
Keloids form as a result of abnormal growth of scar tissue usually 
after  trivial  injury  to  the  skin.  The  cause,  the  inciting  factors,  its 
predisposition to occur in certain races, certain injuries and certain sites are 
still  to  be  explained.  Moreover,  the  phenomenon  is  peculiar  to  humans 
alone.
It  is  a  source  of  distress  to  the  patient,  as  even  though  it  is  not 
malignant,  it  grows  to  enormous  proportions  and is  not  only  a  cosmetic 
deformity but also produces itching, burning pain and bleeding.
Treatment is a frustrating experience  for surgeons, as keloids have a 
marked propensity to recur after excision, the recurrence rate  being as high 
as 45% to 100%. Therefore several other modalities of treatment have been 
tried either alone or in combination with surgery. They include intralesional 
steroid  injections,  pressure  garments,  silicone  gel  sheet  application  and 
various drugs but not with any significant success in rates of control.
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Radiotherapy  following  surgery  has  been  reported  as  the  most 
effective modality at present with control rates at one year of about 90%. 
But  the   traditional  problems with  radiation  therapy have  been  the  field 
irradiation of surrounding normal areas and the remote chance of secondary 
cancer. 
HDR  (High  dose  radiation)  Brachytherapy  that  allows  specific 
deposition of radiation to tissues, only at the desired site and depth, provided 
an answer to the above problems. Many studies have quoted  very good 
control rates with no major side effects. It appears that HDR Brachytherapy 
post surgery could become the ideal management for keloids.
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AIM OF THE STUDY
The current  study was evolved to test  the hypothesis  that  Surgery 
followed  by  HDR  Brachytherapy  was  an  effective  method  of  treating 
keloids.
This study also analysis:
 The age and sex of patients with keloids
 The common sites of occurrence
 The causes for developing keloids
 The clinical signs and symptoms of these patients
 The method of surgery plus radiotherapy employed
 The immediate follow up and condition at one year
 The incidence of complications and recurrence of keloid
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SCIENTIFIC FACTS ABOUT KELOID
Background
A  keloid  is  an  overgrowth  of  dense  fibrous  tissue  that  usually 
develops  after  healing  of  a  skin  injury.  The  tissue  extends  beyond  the 
borders of the original wound, does not usually regress spontaneously and 
tends to recur after excision.
The first  description of keloids  was recorded on Papyrus in 1700 
B.C. Subsequently in 1806, Alibert used the term 'cheloide', derived from 
Greek chele,  or  crab's  claw,  to  describe  the  lateral  growth of  tissue into 
unaffected skin.
Pathophysiology
Hypertrophic (HT) scars and keloids can be described as variations of 
typical wound healing . In a typical wound, anabolic and catabolic processes 
achieve equilibrium approximately 6-8 weeks after original injury. 
At this stage, the strength of the wound is approximately 30-40% that of 
healthy skin. As the scar matures, the tensile strength of the scar improves as a 
result of progressive cross-linking of collagen fibers. At this point, the scar is 
usually hyperemic and it may be thickened, but it tends to subside gradually over 
months until a fiat, white, pliable possibly stretched mature scar has developed. 
When an imbalance occurs between the anabolic and catabolic phases, the scar 
becomes weak or excessive. Excessive scars are classified either as keloid or a 
hypertrophic scar.
Scar Comparison Chart
4
COMPARISON
CRITERIA
KELOID
SCARS
HYPERTROPHI
C
SCARS
CONTRACTURES
Most common
complexion Dark Light N/A
Extends beyond
original wound Yes No
Yes
Respond
to treatment Sometimes Yes Yes
Raised
scarring Yes Yes Yes
Common to 
burn injuries No Yes Yes
Kischer and Brody declared the collagen nodule to be the identifying 
structural unit of hypertrophic scars and keloids. The nodule, that is absent 
from mature scars, contains a high density of fibroblasts and unidirectional 
collagen fibrils in a highly organised and distinct orientation. In addition, 
keloids and HT scars differ from healthy skin by a rich vasculature, high 
mesenchymal cell density and thickened epidermal cell layer. 
The  most  consistent  histological  difference  between HT scars  and 
keloids is the presence of broad, dull pink bundles of collagen in keloids, 
which are not  present  in HT scars.
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Keloids and HT scars are associated generally with HLA-B14, HLA-
B21, HLA BW-16, HLA-BW 35, HLA-DR 5, HLA-DQw3 and blood group 
A.  Transmission  is  reported  as  both  autosomal  dominant  and  autosomal 
recessive. 
8 genes were found to be expressed exclusively in ear-lobe keloid 
fibroblastic cell lines. Coagulation factor (2) thrombin receptor gene, KIAA 
0367 protein gene and matrilin -2 gene were found to be the most commonly 
expressed  genes  in  keloid  cells.  Suppressor  genes  like  melanoma 
differentiation asso-gene-7, Mda-7 (U16261), were expressed in normal skin 
fibroblasts  but  were  not  expressed  in  keloid  fibroblasts  and  may  be 
implicated in the pathogenesis of keloid lesions.
Reprogramming of gene expression or disordered differentiation from 
a  dermal  pattern  to  that  of  a  chondrocytic  /  osteogenic  lineage,  may  be 
involved in etiology of keloid.
Clinical Parameters
Race:  Keloids form more frequently  in Polynesian and Chinese persons 
than in Indian and Malaysian persons.  As  many as 16% of people in  a 
random  sampling  of  black  Africans  reported  having  keloids.  White  and 
albino persons are least commonly affected.
Sex:  The prevalence of keloids has been reported to be higher in young 
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females than in young males, probably reflecting the greater frequency of 
ear piercing among females. Keloids and HT scars affect both sexes equally 
in other age groups.
Age: Onset occurs most commonly in individuals aged 10-30 years. Keloids 
occur less frequently at extremes of age, although an increasing number of 
presternal keloids have resulted from coronary artery bypass operations and 
similar procedures now undertaken in persons of older age groups.
History: Usually the only problem may be cosmetic disfigurement, but HT 
scars and keloids may become tender, painful, pruritic or infected and they 
may  cause  a  burning  sensation.  Sometimes  they  may  cause  contractures 
which may result in loss of function if over a joint.
Physical  characters:  Keloids  manifest  as  exaggerated  growths  of  scar 
tissue, usually in areas of previous trauma. They extend past the areas of 
trauma, projecting above the level of surrounding skin but rarely extend into 
underlying subcutaneous tissue.
HT  scars  remain  limited  to  the  traumatised  area  and  regress 
spontaneously  within  12-18  months,  although  regression  may  not 
necessarily be complete.
 Keloids range in consistency from soft and doughy to rubbery and hard. 
Early lesions are often erythematous. Lesions become brownish red and 
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then  pale  as  they  age.  Usually  are  devoid  of  hair  follicles  and  other 
functioning adnexal glands.
 Most keloids grow for weeks to months, others grow for years. Growth is 
usually slow, but some enlarge rapidly, tripling in size within months. 
Once they stop growing, they usually remain stable or involute slightly.
 Keloids on the ears, neck and abdomen tend to be pedunculated. Keloids 
on the central chest and extremities are usually raised with a flat surface, 
and the base is often wider than the top.
 Most keloids are round, oval or oblong with regular margins, however 
some have claw like configurations with irregular borders.
 Most patients present with 1 or 2 keloids, however a few patients with 
spontaneous keloids, or those who developed it as a consequence of acne 
or chickenpox have multiple lesions.
Sites:
 In  white  persons,  keloids  tend  to  present,  in  decreasing  order  of 
frequency on the face (with cheek and earlobes predominating), upper 
extremities, chest, presternal area, neck, back, lower extremities, breast 
and abdomen.
 In black persons, the descending order of frequency tends to be earlobes, 
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face, neck, lower extremities, breast, chest, back and abdomen.
 In Asian persons, the descending order of frequency is earlobes, upper 
extremities, neck, breast and chest.
Lab Studies: Diagnosis is usually based on clinical findings. Biopsy helps 
confirm the diagnosis in cases of uncertainty.
Histological Findings: Collagen fibers in granulation tissue are arranged 
in  a  whorled  pattern,  the  nodules  grow  and  eventually  show  thick, 
compacted, hyalinized bands of collagen lying in a concentric arrangement.
In keloids, this condensation persists indefinitely. While in HT scars, 
the  fibers  gradually  thin  and  straighten,  so  the  orientation  of  collagen 
bundles appear parallel to the surface of the skin.
TREATMENT
Medical care:  No single therapeutic modality is best for all keloids. The 
location, size and depth of the lesion, the age of the patient and past response 
to treatment determine the type of  therapy used. Prevention is the key, but 
there are no specific causes that are attributable to its occurrence.
Therapeutic  treatment  of  hypertrophic  scars  and  keloids  includes 
occlusive  dressings,  compression  therapy,  intralesional  corticosteroid, 
cryosurgery,  excision,  radiation therapy,  laser  therapy,  interferon therapy, 
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imiquimod  5%  cream,  and  other  promising  but  lesser  known  therapies 
directed at collagen synthesis.
Prevention:  This is the first rule in keloid therapy.
 Avoid performing non-essential cosmetic surgery in patients known 
to form keloids;  However do not consider  patients  who have only 
earlobe lesions to be among those who form keloids.
 Close all surgical wounds with minimal tension.
 Incisions should not cross joint spaces.
 Avoid mid-chest incisions; ensure that incisions follow skin creases 
whenever possible.
 Ensure perfect hemostasis before closure.
 Do not allow healing by secondary intention
 Prevent infection. 
Standard Treatments:
Occlusive dressings: Includes silicone gel  sheets and dressings, non-
silicone occlusive sheets, Cordran tape and Scarguard. Anti keloidal effects 
appear to result from a combination of occlusion and hydration, rather than 
from an effect of the silicone.
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 Silicone occlusive sheeting with pressure when worn 24 hours a day for 
12  months,  34%  of  patients  showed  excellent  improvement,  37.5% 
showed  moderate  improvement  and  28%  demonstrated  no  or  slight 
improvement.
 Of  patients  treated  with  semi-permeable,  semi-occlusive  non-silicone-
based dressings for 8 weeks, 60% experienced flattening of keloids, 71% 
had reduced pain, 78% had reduced tenderness,  80% reduced pruritis, 
87.5% reduced erythema and 90% were satisfied with treatment.
 Cordran tape  is  a clear surgical  tape that contains flurandrenolide, a 
steroid that is uniformly distributed over each square centimeter of the 
tape, and has been shown to soften keloids over time. Scar guard is a 
topical  medication containing silicone,  hydrocortisone and Vitamin E. 
This stimulates the release of inactive collagenase precursors that may 
inhibit new scars forming and reduce existing scars. In a pilot study of 12 
patients, Scarguard was applied twice daily, after the removal of a mole, 
and nothing was applied on a control mole scar. After 2 months, 9 of 12 
patients reported that the treated scar was less red and less noticeable 
compared with the untreated scar.
  In a major meta-analysis of 13 trials involving 559 people, the authors 
reported  that  there  was  great  bias  in  reporting  that  silicone  sheets 
prevented  or  were  effective  in  controlling  HT  scars  and  keloids  and 
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cautioned that a great deal of uncertainty prevails.
Compression therapy:  Involves pressure which has long been known to 
have thinning effects  on skin.  Reduction in the  cohesiveness of  collagen 
fibers  in  pressure-treated  HT  scars  has  been  demonstrated  by  electron 
microscopy.
 Compression treatments include button compression, pressure earrings, 
ACE bandages,  elastic  adhesive  bandages,  compression  wraps,  Lycra 
bandages and support bandages. In one study, button compression of the 
earlobe prevented recurrence during 8 months to 4 years of follow-up 
observation.
 Other  pressure-gradient  garments  are  made  of  light  weight  porous 
Dacron,  Spandex (also known as elastane) or bobbinet fabric (usually 
worn 12 - 24 hours a day) and Zinc 0xide adhesive plaster. Overall, 60% 
of patients treated with these devices showed 75 - 100% improvement.
 A major problem in patients surviving thermal injury is the development of 
hypertrophic  burn  scars.  A  study  was  performed  to  determine  the  factors 
associated  with  an  increased  risk  of  the  development  of  hypertrophic  burn 
scars. Fifty-nine children (mean age, 3 years; mean TBSA, 14%) and 41 adults 
(mean age, 37; mean TBSA, 21%) followed from 9 to 18 months formed the 
study group. The location as well as the time required for the burns to heal 
were recorded in addition to the age and race of the patients. Sixtythree (26%) 
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of  the  245  burn  areas,  in  these  100  patients,  became  hypertrophic.  No 
correlation between patient age and the development of wound problems was 
found. Blacks had more wound problems than others, if the burn wound took 
longer than 10 to 14 days to heal.  The most important indicator of whether 
wound problems would occur was the time required for the burn to heal. If the 
burn wound healed between 14 and 21 days then one third of the anatomic sites 
became  hypertrophic;  if  the  burn  wound  healed  after  
21 days then 78% of the burn sites developed hypertrophic scars. Based on 
these findings, the authors developed a protocol to prescribe pressure garments 
selectively to those areas that would hypertrophy.
Corticosteroids:  Intralesional  corticosteroid  injections  have  been  the 
mainstay  of  treatment.  Steroids  reduce  excessive  scarring  by  reducing 
collagen  synthesis,  altering  glycosaminoglycans  synthesis,  reducing 
production of inflammatory mediators and fibroblast   proliferation during 
wound healing.  The most  commonly  used corticosteroid  is  triamcinolone 
acetonide  (TAC)  in  concentrations  of  10  to  40  mg  /  ml,  administered 
intralesionally with a 25 - 27 G needle at 4 - 6 week intervals.
 Intralesional steroid therapy either singly or as an adjunct to excision has 
showed response rates of 50 - 100%, with recurrence rates of 9 - 50% in 
completely resolved scars.
 Complications  of  repeated  corticosteroid  injections  include  atrophy, 
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telangiectasia formation and pigmentary alteration.
Recent innovations:
1.  Interferon: Interferon  α,  Interferon  β and  Interferon  γ have  been 
demonstrated in in-vitro studies to reduce keloidal fibroblast production of 
Collagen I,  III and VI mRNA. Interferon  α and Interferon  β also reduce 
production  of  glycosaminoglycans  (GAG)  that  forms  the  scaffolding  for 
deposition  of  dermal  collagen.  Interferon   α,β and  γ also  increase 
collagenase activity by modulating a p53 apoptotic pathway. p53 is a potent 
suppressor of interleukin (IL)-6, a cytokine implicated in hyperproliferative 
and fibrotic conditions. 
Interferon injected into the suture line of keloid excision sites may be 
prophylactic for reducing recurrences. Berman and Flores reported statistically 
significant fewer keloid  recurrences in a study of 124 keloid lesions after post-
operative interferon - α2b injection treatment (5 million units, 1 million unit 
injected per cm of scar) into keloid excision sites (18%) versus excision alone 
(51.1%) and TAC treatment (58.4%).
2.  Verapamil: is  a  calcium channel  blocker  that  blocks  the  synthesis  / 
secretion  of  extra  cellular  matrix  molecules  (eg.  Collagen,GAGS, 
fibronectin) and increases fibrinase. In a study of 22 patients with keloids, 
patients were treated with surgical excision and 5 treatments of Verapamil at 
2.5 mg / ml (doses varied from 0.5 to 5 ml depending on the size of the 
keloid) over a 2 month period and were evaluated at 2 year follow-up. Two 
patients  had  keloids  that  decreased  in  size,  from  the  original  lesion,  2 
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patients had hypertrophic scars, 4 patients had pruritis, and one patient had a 
keloid on the donor site.
3.  Bleomycin: injections  cause  necrosis  of  keratinocytes  with  a  mixed 
inflammatory infiltrate. In a study, Bleomycin was given at a concentration 
of  1.5  I.U.  /  ml  to  13  patients  using  the  multiple  puncture  technique.  7 
patients had complete flattening, 5 patients had highly significant flattening, 
and one patient had significant  flattening. In another study on 31 patients 
treated  with  3-5  infiltrates  of  Bleomycin  within  a  1  month  period,  total 
regression occured in 84% of keloids.
4. 5FU: a pyramidine analog, inhibits fibroblastic proliferation. In one RCT 
(randomised,  controlled  trial),  28  patients  were  treated  with  weekly 
injections of 05. - 2 ml at a 50 mg / ml concentration of 5FU for 12 weeks. 
At 24 week follow up, 70% of patients had more than 50% improvement in 
keloid size.
In  another retrospective study of  1000 patients  with HT scars  and 
keloids over a 9 year period, the most effective regimen was found to be 0.1 
ml of TAC (10 mg / ml) and 0.9 ml of 5FU (50 mg/ml) upto 3 times a week.
5. Retinoic acid: decreases normal tonofilament and keratohyalin synthesis, 
increases production of mucoid substances and epidermal growth rate and 
inhibits DNA synthesis in vitro. In a clinical trial involving 21 patients with 
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28 keloids  and HT scars  topical  retionic  acid  was applied  for  at  least  3 
months twice daily and showed favourable results in 77 - 79% of lesions. 
There was a decrease in  the  size and symptoms of the scar.
6.  Imiquimod  :  Used  as  a  5%  cream  induces  TNF,  interferon  α and 
γ,IL1,IL6,IL8 and IL2.It alters the expression of markers for apoptosis. In 
one  study,  13  keloids  were  treated   with  excision  in  combination  with 
nightly  applications  of  imiquimod  for  8  weeks.  Ten  patients  with  
11 keloids  completed the  6 month study and no keloids  recurred after  6 
months.  Mild  irritation  and  hyper  pigmentation  were  the  side  effects 
experienced.
7. Tacrolimus:- is an immunomodulator that inhibits TNF-α  and gli-1 an 
oncogene  that  has  been  found  over  expressed  in  fibroblasts  of  keloids. 
Rapamylin,  a  close  analogue  of  tacrolimus  was  found  to  inhibit  gli-1 
oncogene  in  vitro.  In  a  pilot  study,  11  patients  used  tacrolimus  0.1% 
ointment  twice  daily  for  12 weeks on their  keloids.  Although the results 
were not statistically significant, the study showed a decrease in induration, 
tenderness, erythema and pruritis for most patients.
Radiotherapy
Radiotherapy  has  been  used  for  the  treatment  of  keloids  from 
1906.Initially deep X-Ray therapy was used followed by Cobalt irradiation. 
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Thereafter  all  the  various  modes  of  radiation  like  α,  β and  gamma 
irradiation  were used. These were hampered by poor patient compliance due 
to the local side effects of radiation like eczema, fear of radiation injury to 
normal tissues and the high costs involved in treating a benign condition. 
Then  came  the  era  of  Brachytherapy  with  surface  applicators  and 
intracavitary rods. This has found wide favour and is routinely used  now.
 In  one  retrospective  study of  superficial  X-ray  therapy of  24  excised 
keloids, the author reported a recurrence rate of 53%. Use of iridium 192 
interstitial  radiation  after  excisional  surgery  resulted  in  a  2  1% 
recurrence  rate  after  one  year.  Excisional  surgery  and  pre-operative 
hyaluronidase solution (150U/ml NaCl) followed by external radiation 
(7.2  -  10.8  Gy)  had  a  0%  recurrence  rate.  Adjunctive  high  dose 
brachytherapy (Ir 192) used after excision and closure resulted in a 12% 
recurrence rate after 26 months.
 When excisional surgery is followed by postoperative radiation therapy, 
the total fractionated dose should be minimum of 12 Gy, according to a 
comparative study showing a higher recurrence rate for patients treated 
with total doses less than 12 Gy.
Surgical care
Cryotherapy
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 Cryosurgical media (eg. liq.nitrogen)  affects the micro vasculature and 
causes cell damage via intracellular crystals leading to tissue anoxia.
 Generally 1, 2 or 3 freeze- thaw cycles lasting 10 - 30 seconds each are 
used for the desired effect. Treatment may need to be repeated every 20 - 
30 days. Cryotherapy may cause pain and hypopigmentation in certain 
patients.
 As  a  single  modality,  crysurgery  led  to  total  resolution  with  no 
recurrences  in  51  -  74%  of  patients  after  30  months  of  follow-up 
observation.
Excision
Certain techniques  have been proposed to  reduce the  incidence of 
keloid in sutured wounds.
 Apply  basic  soft  tissue  handling  techniques  at  primary  wound  repair 
sites.
 Carefully plan closure with minimal tension, paralleling the relaxed skin 
tension lines.
 Use buried  sutures  when necessary  for  layered closure  and to  reduce 
tension.
 Apply  pressure  dressings  during  immediate  post-  operative  period  to 
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wounds of patients in whom HT scars and keloid formation occur.
 Excisional  surgery  of  keloids  alone  has  been  shown  to  yield  a  
45 - 100% recurrence rate, and should very rarely be used as a solitary 
modality.  Combination  therapy  with  radiation,  interferon  and 
corticosteroids  have reduced recurrence rates.
Laser therapy
 Ablation of keloids and HT scars using a CO2 laser (10,600 nm) can cut 
and  cauterize  the  lesion,  creating  a  dry  surgical  environment  with 
minimal tissue trauma. When used as a single modality, the CO2 laser 
was associated with recurrence rates of 39 - 92% and when combined 
with post operative steroids, it was associated with 25 - 74% recurrence 
rates.
 The Argon laser (488 nm) similar to the C02 laser can induce collagen 
shrinkage via generation of excessive localised heat. The argon laser has 
demonstrated recurrence rates of 45 - 93%.
 The pulsed dye laser (585 nm) provides photothermolysis, resulting in 
microvascular thrombosis. Beginning in 1980s, authors noted that scars 
become  less  eythematous,  more  pliable  and  less  hypertrophic  after 
treatment with 585 nm pulsed dye laser. This remains the laser treatment 
of choice for HT scars due to its safety, efficacy and relatively low cost.
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 The Nd-YAG laser (106 nm) has demonstrated recurrence rates of 53 – 
100%.
Other potential therapies
Agents that affect collagen and GAG synthesis like proline -  cis - 
hydroxyproline  and azetidine  carboxylic  acid,  tranilast  (antiallergic  drug) 
and pentoxifyline (inhibits DNA replication) have been research tools.
Wounds treated with anti-transforming growth factor (decorin) heal 
with minimal scar tissue formation without affecting wound tensile strength.
Further outpatient care
 Because of the high rate of recurrence, a follow up period of one year is 
necessary to evaluate effectiveness of therapy
 Advise patients to avoid sharp trauma to skin.
 Minimize inflammation resulting from acne or surgery.
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REVIEW OF LITERATURE
Radiotherapy as a single modality or in combination with surgery has 
been used to treat keloids from as early as 1906.
It has been given in various ways: X-ray (energy = or less than 100 
KV) therapy,  Teletherapy with photon irradiation or  electron  (5 MeV or 
less) and Brachytherapy eg.192 Iridium wires. 
 The biologically effective dose (BED) is a relatively high dose that must 
be applied in a short overall treatment time. A BED value of 30 GY was 
reported  as  optimal,  the  treatment  administered  within  2  days  after 
surgery. Doses less than 10 GY were not effective.
 In  83  keloids  on  66  patients  treated  with  4  x  5  GY (Strontium -  90 
surface  applicator),  61%  patients  were  extremely  satisfied  with 
therapeutic  outcome  and   51%  were  extremely  satisfied  with  the 
cosmetic outcome. The relief from former keloid-caused symptoms, the 
ear as keloid localisation and male gender were significantly associated 
with  higher  satisfaction.  The  recurrence  rate  as  well  as  the  extent  of 
radiation  side  effects  had  no  significant  influence  on  patients’ 
assessment.
 139 patients with 166 keloids treated from 1962 to 1996 were evaluated. 
Within 48 hours of surgery, they were treated with brachytherapy using 
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Strontium 90 applicator. Median dose to subcutis was 14 GY (7.5 to 28.5 
Gy).  Overall  recurrence  free  response rate  was  80%.  Recurrence  was 
lowest (2%) with keloids of face and neck and highest with keloids over 
thorax (49%), Keloids following burns had a poorer success rate than 
those developing after surgery or mechanical trauma (p<0.001). There 
was  no  difference  in  outcome  related  to  gender,  age  or  size.  No 
secondary malignancy was reported in 12 years followup.
 169 patients were treated with HDR brachytherapy between December 
1991 and December 1998. 134 were females and facial keloids were a 
maximum. Within 60 min.  of  surgery,  HDR Brachytherapy in a total 
dose  of  12  GY  was  administered  in  
4  fractions  of  300 cGY in  24  hours.  After  a  follow up  of  7  years,  
5 patients had keloid recurrence. Cosmetic results were considered to be 
good or excellent in 130 / 147 patients. Skin pigmentation was observed 
in  10  patients,  telangiectasias  in  
12 patients. No late effects of skin atrophy or fibrosis were observed.
 HDR  Brachytherapy  was  preferred  to  X-rays  or  low  energy  electron 
beams as HDR provides a better selective deposit of radiation in tissues 
and lower degree of normal tissue radiation. Other advantage of HDR 
brachytherapy over low dose rate brachytherapy are its low cost and the 
fact that it can be performed as an out patient basis. Gives a good local 
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control rate without significant sequelae or complications.
 Leibel  and Phillips  used  dose  regimens  of  9  -  16 GY in 3 to  4  GY 
fractions. Excellent cosmetic results have been reported in 95% of cases, 
and relapse rates range from 2 % to 27%. Perez describes doses of 10 - 
15 GY given in 2 - 3 fractions.
 Berman B. Bieley used 10 GY in 1 fraction or 12 to 16 GY in 3 to 4 
fractions (400 ccy x 3 to 4 fractions) and has obtained good results. The 
authors  concluded  that  radiation  therapy  using  various  protocols,  has 
been a safe and efficacious modality in reducing recurrence.
 In another study, 36 patients underwent earlobe keloid excision followed 
by 1800 cGY of radiation therapy in three equally divided doses over 5 
to 7 days. In a follow-up of 5 - 6 years, there was only one recurrence 
(2.8%). One patient developed radiation dermatitis followed by patchy 
hypopigmentation.
 Beta  radiation  alone  was  found  to  be  effective  in  the  eradication  of 
symptoms (55% relief), while results in the reduction of size of lesions 
have  been  poor  (11%).  Surgery  combined  with  postoperative  beta 
radiation therapy yielded a 67% success rate. The success rate was 75% 
when  radiation  was  delivered  within  
48  hours  of  surgery.  Preoperative  radiation  was  found  to  be  of  no 
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advantage.
 203 Keloids were excised and postoperative kilovoltage irradiation was 
given to prevent regrowth, in Iowa University hospitals. A minimum of 
one  year follow up was advised to evaluate results. Likelihood of failure 
was too great to justify routine use of less than 900 cGY. A dose greater 
than or equal to 1500 cGY was sufficient to control 90% of them without 
re-excision.
  Another study compared the efficacy of ortho-voltage and electron beam 
radiation.  126  keloids  were  treated  with  surgery  followed  by 
radiotherapy and after a median follow up of 12 years it was concluded 
that higher post treatment recurrence were noted with keloids forming at 
infected sites and in patients with family history. No increased likelihood 
of  recurrence was noted with respect  to  patient  age,  sex or  ethnicity, 
keloid  size  or  location,  individual  keloid  history,  or  prior  therapy  or 
radiation type used. The results showed that radiation therapy is a useful 
and effective method of keloid eradication and electron beam radiation 
offers no advantage over orthovoltage radiation.
 75 patients with 113 keloids, 74% involving the ear lobes was treated 
with superficial X-ray therapy with a most frequent dose schedule of 12 
GY in 3 fractions over 3 days. Control rate was 73%. Keloids greater 
than 2 cm, those that had previous therapy, and those occurring in men 
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were found to indicate a high likelihood of recurrence. The mean time to 
recurrence  was  
12.8 months. There was no complication from this low dose treatment.
 A German study  used an automatic water phantom to evaluate the dose 
distribution in tissue. Further more, a series of measurements were done 
on patients using thermoluminescence dosimeters (TLD) to estimate the 
doses  absorbed  by  the  organs  at  risk.  134  keloids  were  treated  with 
electron beam irradiation following surgical excision. A high control rate 
of  84%  with  minimal  side  effects  was  observed.  Electron  radiation 
provides  better  dose  distribution  in  tissue and therefore  less  radiation 
burden to organs at risk. After a mean follow up of 7.2 years, no severe 
side effects or malignancies were observed.
 A  study  from  Japan  between  the  years  1988  and  1994  treated  110 
patients  with 139  keloids with surgery and post  operative irradiation 
with  a  4  MeV  electron  beam,  1-3  days  after  surgery,  for  three 
consecutive days. The total doses were 15 GY or 18 GY. Control rates 
for  keloids  and  hypertrophic  scars  were  
76% (57 / 75) and 93.8% (60 / 64) and overall effectiveness was 84.2%. 
No remarkable side effects or malignancy was observed. So they have 
dispensed with low energy X-ray machines as  electron beam delivers 
peak dose at the site of keloid and the  depth of penetration is limited.
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 In  1989 Sallstrom published  his  results  on  treating  124 patients  with 
keloids with surgery and post operative X-ray radiation, begun within 24 
hours of surgery. Patients with a two year history of keloid were included 
and good or excellent results were observed in 24 months followup in 
92%. Slight hyperpigmentation was found in 31% and telangiectasis in 
l5%.
 A prospective randomised trial comparing the efficacy of corticosteroid 
injection and radiotherapy after excision of 31 keloids, showed that 2 of 
16  keloids  (12.5%)  recurred  after  radiotherapy,  while  4  of  12  (33%) 
recurred after intra lesional steroid. Radiotherapy was found to be more 
effective in preventing recurrence.
 11 sternal keloids in patients 14 to 16 years of age were treated with 
surgery, skin grafting and radiation therapy. RT was given to suture lines 
only using 3 doses of 500 cGY each, within 7 to 14 days of surgery. 
Follow up ranged from 1 to 24 years.  Only one patient  demonstrated 
recurrence. Six patients received post-operative episodic steroid injection 
for itching or nodule formation without a recurrence.
 The data of 139 patients with 166 keloids between 1962 and 1999 was 
evaluated for prognostic  factors  and outcomes.  Treatment commenced 
within 48 hours after surgery. Radiotherapy was given as brachytherapy 
using  an  integrated  radionuclide  90Sr-  90Y  surface  applicator.  The 
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median dose delivered subcutis was 14 GY (7.5 to 28.5GY). The overall 
recurrence free response was 80%. Response rates differed significantly 
(p<0.001). The recurrence was lowest with keloids of face and neck (2%) 
and highest with keloids of thorax (49%). Keloids following burns had a 
poorer success rate than those developing after surgery or mechanical 
trauma (p<0.001). There was no difference in outcome related to gender, 
age or size.
 In another similar study from Japan, 378 cases of keloids were surgically 
removed and patients treated with 15 GY electron beam irradiation and 
followed  for  18  months.  Recurrence  occurred  in  
2 sites on 14 earlobes (14.3),in 2 sites on 12 necks (16.7%), 22 of 51 
anterior chest wall (43.1%), in 13 sites in 33 scapular regions (39.4%), in 
four  sites  on  15  upper  limbs  (26.7%),  in  4  sites  in  
11 suprapubic regions (36.4%) and one site in 11 lower limbs (9.1%). 
The overall recurrence was 32.7%. High stretch tension regions of chest, 
scapula  and  suprapubic  regions  showed  a  higher  recurrence  that  the 
authors  suggested  to  be  treated  with  escalating  doses  of  radiation 
therapy.
 In  a  landmark  study  by  Raj  Ragoowansi  et  al,  80  keloid  scars  were 
treated (59% female and 76% non-white) and 44 percent were located on 
earlobes. For all patients prior treatment without radiotherapy had failed. 
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In  this  study  extralesional  excision  was  followed  with  immediate 
external beam radiotherapy. A 10 GY dose of superficial 60 kV or 100 
kV photon irradiation was given within 24 hours of the operation. The 
main outcome measure  was freedom from recurrence of  keloid scars. 
Results were that all keloid scars were controlled at 4 weeks. Probability 
of relapse at one year was 9 percent and at 5 years was 16 percent. The 
earlobe showed no greater chance of relapse than other sites on the body.
 In reviewing the text of published articles and in MEDLINE searches for 
radiation induced cancers, only five cases of possible radiation induced 
cancers after keloid treatment have been documented. Radiotherapy has 
been used frequently and one series has followed patients for up to 20 
years  and found  no  cancer  induction.  One  case  of  thyroid  carcinoma 
occurring  in  a  potential  exit  dose  site  was  reported  8  years  after  the 
treatment of a keloid on the chin of an 11 year old child, but subsequent 
investigations raise some doubts about causation.
A  second  case  involves  bilateral  breast  cancer  developing  
29  years  after  radiotherapy  for  chest  wall  keloid  treatment  given  at  
26  years  of  age.  In  a  third  case,  a  basal  cell  carcinoma  developed  
10  years  after  radiotherapy.  A  fourth  case  is  of  a  parathyroid  adenoma 
occurring 38 years after RT to the neck for keloids when the patient was 10 
years old. A fifth case is of a 36 year old woman who had a localised fibrous 
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mesothelioma of the pleura and an ipsilateral breast carcinoma 23 years after 
receiving external radiation therapy at 13 years in the  treatment of a chest 
wall keloid. 
From  literature  review,  there  is  documentation  that  about  6741 
keloids have been treated with radiotherapy. With these 5 cases, the crude 
risk of developing cancer after radiotherapy is 5:6741 or 1:1348. Cancer is 
diagnosed  each  year  in  1  in  every  250  men  and  
1 in every 300 women. It is difficult therefore to assign risk of radiotherapy 
without  a  defined  population  of  exposed  cases  and  matched  controls  to 
compare and without a long-term follow-up.
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PATIENTS & METHODS
This  study  was  carried  out  in  the  Departments  of  Plastic  and 
Reconstructive  Surgery,  Kilpauk  Medical  College  and  Government 
Royapettah  Hospital  and  in  the  Department  of  Radiation  Oncology, 
Government General Hospital and Dr. Rai Memorial Hospital.
The period of study was from June 2004 to January 2006.
Patients seeking treatment for keloids and attending the Out Patient 
Departments of Plastic Surgery were candidates for the study. Most patients 
had  keloids  that  were  at  high  risk  for  relapse  because  they  had  been 
previously excised and had recurred. The patients were chosen at random 
and the study group consisted of 15 patients. Keloidal scars of any duration, 
any etiology and any site were enrolled into the study. The only patients 
excluded were children below twelve years of age.
A patient proforma was filled up detailing the history (duration, site, 
etiology,  symptoms,  previous  treatment  history  and  family  history);  the 
clinical  features  (site,  size,  surrounding  skin,  similar  lesions  elsewhere, 
ulcers, infection, appearance and quality of skin).
An informed consent was obtained from the patient. The treatment 
plan,  the  advantages  and  problems  of  the  procedure,  the  necessity  of 
stringent follow-up were explained. The other treatment options available 
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were also highlighted.
The keloid was then excised extralesionally  except  in  a  few large 
earlobe  /  helical  keloids  where  intralesional  excision  preserved  available 
normal skin, under local or general anaesthesia as the case required. The 
wound was closed primarily without tension in one or two layers of non-
absorbable simple sutures, after securing complete hemostasis.
The  patient  was  given  HDR  Brachytherapy  starting  on  the  first 
postoperative  day.  A mould  of  the  operated  site  was  prepared  with  two 
layers of dental compound and 2 micro catheters were sandwiched within it 
and strapped to it at a distance of 1 cm from each other. The mould was then 
fixed to the operated scar, the catheters at 5 mm on either side of the scar. 
These  catheters  were  then  attached  to  the  HDR  brachytherapy  unit  and 
Iridium 192 seeds were passed through it to reach the target i.e. the suture 
line.
          4 fractions of 500 cGY, a total of 2000 cGY were given, with a 
minimum of 6 hours gap between fractions and the treatment was completed 
within 72 hours of Surgery. 
In  some patients,  radiotherapy was given with a  linear  accelerator 
delivering  1500  -  2000  rads  to  the  suture  line  using  a  
6 MeV machine that delivered approximately 2000 rads to the sub cutis. The 
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source was kept in contact with the operated site, the beam was centered on 
the scar and all surrounding tissue was shielded with lead bars. This 
was given within 24 hours of surgery.
In both cases, the applied dose point was 100% at the Dmax, which 
was  at  the  skin  surface  for  this  superficial  therapy.  The  
90 percent isodose target area was the operated scar. The maximum depth of 
penetration of radiation was 0.5 cm in HDR brachytherapy and 1 cm in a 
linear accelerator. This was achieved by using biological tissue equivalents. 
In  the cases where both anterior and posterior sides had to be irradiated, for 
example in the earlobes, the depth of penetration was kept at 2cm. 
Clinical photographs were taken 
 pre-operatively
 during brachytherapy
 at suture removal and   
 during follow-up visits.
Sutures were removed on the 7th to the10th postoperative day. All 
patients were routinely advised to wear compression garments.
          Patients were followed up
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 Weekly for the first two weeks or until suture removal
 Once a month for 3 months
 Every 2 months for 1 year.
During each visit note was made of
 Scar widening or hypertrophy
 Any local side effects
 Systemic complaints
 Recurrence at site of surgery
Recurrence was defined as the clinical evidence of a nodule or obvious 
return of lesion.
End point  of  study: Combined modality  treatment  -  Surgery  with 
HDR Brachytherapy, was concluded to be effective if no recurrence of the 
lesion was detected at One year.
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OBSERVATION
 15 patients in this study included 13 women and 2 men making a male: 
female ratio of 1 : 6.5.
 The age range of the patients:
Age 13 - 20 yrs 21 - 30 yrs 31 - 40 yrs >40 yrs
Number 5 5 4 1
 The duration of the keloids in these patients ranged between        6 
months to 18 years.
 The ear was the most common site of involvement seen in 11 out of 15 
cases. In five cases, the helix (site of secondary ear boring) and in 6 cases 
the ear lobe had keloids.
 In  5  cases,  both  the  anterior  and  posterior  surfaces  of  the  ear  were 
involved.
 4  patients  had  bilateral  involvement.  In  such  cases,  both  sides  were 
operated but only one side was irradiated. The other side therefore acts as 
a control.
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 The sites that were found in this series are :
Ear - 11
Chest -   1
Neck -   1
Shoulder -   1
Face -   1
 Trauma  and  infection  were  found  to  be  the  most  common  inciting 
factors.  Trauma  ranged  from  minor  injury  due  to  nail  scratch  to 
significant trauma like a cut with a sunmica sheet or surgery.
 The initiating causes are as described:
S.No. Causes Number
1. Earboring 4
2. Infection Complicating Earboring 3
3. Major Trauma 3
4. Nail Scratch 2
5. Incision & Drainage of Abscess 2
6. Ear Lobe Repair 1
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 All patients requested treatment because of the unsightly nature of the 
keloid.  6  patients  also  complained  of  occasional  itching  and  
4 patients of a dull pain exacerbated by accidental trauma to the lesion.
Bias in the Study :
 There has been an unconscious bias in recruiting cases that have been 
recalcitrant  to  previous  treatments,  as  11  out  of  15  cases  have  had 
surgical excision of the lesion before and has since recurred. 3 cases had 
been operated twice and one case thrice before.
 Similarly  8  of  15  cases  have  had  courses  of  steroid  injections,  
3 patients had been injected twice and one patient had 20 injections over 
3 courses.
 The list of previous treatments that had been done for   keloids in this 
series were:
Treatment Number %
No prior treatment  3 (20%)
Surgery 11 (73%)
Steroids   8 (53%)
Ointments   2 (13%)
Silicone gel    1 (6.6%)
Others (homeopathy, acupuncture)  1 (6.6%)
The  size  of  the  lesions  was  again  a  wide  range,  starting  from  
5 mm x 5 mm in an ear lobe keloid to 9 x 3 cm keloid on the anterior chest.
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Size 5 mm. to 2 cm. 3 cm. to 5 cm. > 5 cm.
Number 7 4 4
Keloids that blanched on pressure and appeared erythematous were 
found in 2, whereas the rest were firm to hard mature lesions. One lesion on 
the  face  that  had  been  operated  thrice  earlier  had  both  mature  and 
erythematous areas.
With regards to skin texture, in this series there was no difference in 
the occurrence of keloids in fair, brownish or dark skinned people, but oily 
and thin-skinned people were more in number (11 : 4).
HDR Brachytherapy was given in 9 patients and the linear accelerator 
was used in 6.The patients had no major problems during the administration 
of  radiotherapy but  for  some tenderness  due to the      handling of  the 
operated scar. 
The  clinical  picture  during  follow-up  is  depicted  in  the  tabular 
column:
Follow-up
Time Pain Itching Nodule Recurrence
2 weeks No No No No
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4 weeks
6 months
1 year
No
1
No
No
2
1
No
1
No
No
No
1
 The keloid scar irradiated on the upper chest developed a nodule in 6 
months and recurred as a hypertrophic scar at 1 year.  The patient has 
been advised salvage therapy with silicone gel  sheet  and compression 
garment.
 1 patient complained of pain at 6 months, a small stitch granuloma was 
observed, that subsided with removal of remnant suture and antibiotics.
 2  patients  complained  of  itching  at  6  months  and  were  treated  with 
antihistamines, but the scars were supple with no evidence of recurrence.
In this series, only one case has registered a treatment failure [1 in 
15 ] giving a recurrence rate of 6.66% 
The control of ear lobe keloids has been 100% at one year.
The complications  encountered during  therapy were  all  minor  and 
transient.
 2 patients developed hyper pigmentation that settled in 6 months.
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 3 patients had an immediate erythema after radiotherapy that subsided in 
2 weeks. 
 One  patient  whose  keloid  in  the  neck  was  irradiated  developed  an 
ipsilateral  facial  oedema  on  the  first  post-radiotherapy  day,  that 
disappeared in 2 days.
 A 45-year-old lady, whose large helical keloid was excised, developed a 
wound gape at suture removal that healed without a hypertrophy in a 
week's time.
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DISCUSSION
This study reinforces certain facts about keloids.
Sex: There  is  a  higher  prevalence of  keloids  in young females.  Studies 
have quoted figures of 60% (Raj Ragoowansi et al) and 80% (Guix et al) of 
patients being female. In this study too the male: female ratio is 1:6.5, the 
increased incidence mainly  because of the common practise of ear boring in 
females.
Age: Keloids affects young people between 10 - 30 years. In most studies 
in the literature the mean age is between 25 to 30 years. The mean age of 
this  study  group  is  27  years.  As  it  afflicts  the  young,  it  is  even  more 
important to provide a lasting solution to this problem.
Site: The common sites reported in the literature are:
Berman et al Guix et al Borgognoni et al This study
   Earlobes
   Upper Extremities
   Neck
   Breast
   Chest
    Face
    Trunk
    Extremities
Ear
Trunk
Upper limb
Ear
Trunk
Face
Neck
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Etiology:  Keloids  are  known  to  occur  with  relatively  minor  trauma  in 
contrast to hypertrophic scars. Spontaneous occurrence has been reported in 
certain genetically predisposed individuals. Wounds that cross skin tension 
lines,  thick  skin  or  in  locations  like  the  earlobe,  
pre-sternal and deltoid regions are more susceptible to abnormal healing.
Earboring alone or the bored site becoming infected was the cause in 
50% of this series.
The enigma of the pathology of keloid was illustrated in the case of a 
lady  with  recurrent  keloid  on  the  chin,  who  had  normal,  supple 
submandibular  and  neck  scars.  The  same patient  also  had  a  very  strong 
familial  disposition  -  her  grandmother,  father  and  son  have  keloidal 
tendencies.
Symptoms: In most series, cosmetic disfigurement remains the main reason 
for seeking treatment, as in this study. The incidences of pain and itching 
were low, 3% and 4% respectively. Many women with ear keloids expressed 
an inability to wear earrings because of the bulky lesions.
Inclusion Criteria:  Because of the possibility of radiation to surrounding 
normal  tissues  and the  remote  chance  of  radiation  induced cancer,  most 
series  have  offered  radiotherapy  only  to  patients  with  recurrent  keloids. 
These  patients  having  been  subjected  to  multiple  surgeries,  courses  of 
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steroid injections and other   therapies to no avail, are highly motivated to 
accept the risk of radiotherapy to obtain a cure. 
In  this  study,  73%  of  patients  have  had  their  lesions  surgically 
excised  previously  and  53% have  tried  steroid  injections.  Ledercort  and 
Contratubex are the most common ointments tried. Recurrence with surgery 
alone has  been reported to  be  45 -  100%. In  completely  resolved cases, 
recurrence following steroid injections is anywhere between 9 - 50%.
Radiotherapy following surgery therefore has been recommended as the 
standard treatment of recurrent keloids. 
This has been given in various ways.
External irradiation
Author Recurrence (%)
Kovalic 27
Maarouf` 16
Sclafani 12.5
Raj Ragoowanshi 9
Berman 10
Chaudhry 2-8
Darzi 25
Linear Accelerator
Author Recurrence (%)
Sallstrom 8
Mitsuhashi 16
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Doornbos 10
Leibel & Phillips 2 - 27
Strontium 90 applicator
Author Recurrence (%)
Fraunholz 36
Wagner 20
HDR Brachytherapy (Ir 192)
Author Recurrence (%)
Garg 12
Guix 3.4
It  has  therefore  been  found  that  radiotherapy  has  been  uniformly 
effective  in  bringing  down  the  recurrence  rate.  The  control  was  more 
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effective  in  patients  with  facial  keloids  (2%)  than  with  thoracic  keloids 
(49%).  This  result  was  statistically  significant  according  to  Wagner  (p= 
0.001).
The symptoms of keloid, like pain and itching were also considerably 
reduced i.e. p = 0.0005 (Fraunholz). 60% of patients were satisfied with the 
cosmetic outcome.
Kal  et  al  calculated  biologic  effective  doses  and  stressed  that  a 
relatively high dose (preferably 30 GY) should be applied in an overall short 
treatment time (preferably within 2 days of surgery).
This  is where HDR Brachytherapy scores over other modalities as 
high doses can be imparted locally within a short time.
In this study, the overall control rate has been 93.3% and compares 
favourably with literature.
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The  most  common  problem  reported  in  the  literature  is  hyper 
pigmentation, but authors have stressed that it is self limiting.
Guix -  6.8%
Mitsuhashi -  44%
Sallstrom -  31%
This series -  13%
There  has  not  been  a  major  adverse  event  or  a  proven  case  of 
secondary malignancy reported so far.
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CONCLUSION
 Keloids are a vexing problem for patients and plastic surgeons.
 Once they occur, a single modality treatment is fraught with recurrence.
 Post  excisional  radiotherapy  affords  good  control,  but  with  the 
disadvantage of radiation to normal tissues.
 HDR Brachytherapy offers an ideal solution as -
Can be done in an out patient basis 
Relatively low cost 
Excellent radiation protection 
Better dose distribution to tissues.
 With a local control rate of  93%  and no significant side effects, HDR 
Brachytherapy following surgery is an effective treatment of keloid scar.
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